Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
3 Biotech Stocks to Buy on the Dip: April 2024
06:00am, Friday, 26'th Apr 2024
If you follow Warren Buffett's advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlyin
Cytokinetics to Announce First Quarter Results on May 8, 2024
04:00pm, Wednesday, 24'th Apr 2024
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
09:27am, Wednesday, 10'th Apr 2024
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy
Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and Function Treatment with Aficamten for 48 Weeks is
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 02'nd Apr 2024
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
04:00pm, Monday, 01'st Apr 2024
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pa
7 Biotech Stocks Ready to Ride the Sector's Resurgence
08:01pm, Monday, 18'th Mar 2024
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
Cytokinetics: CEO Talks Down Buyout Prospects
03:43am, Saturday, 16'th Mar 2024
Cytokinetics: CEO Talks Down Buyout Prospects
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
02:25pm, Wednesday, 13'th Mar 2024
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno
Cytokinetics to Participate in March Investor Conferences
04:00pm, Monday, 04'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
06:11pm, Tuesday, 27'th Feb 2024
Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.45 per share a year ago.
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
04:00pm, Tuesday, 13'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
09:10am, Thursday, 08'th Feb 2024
The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
04:32pm, Friday, 12'th Jan 2024
Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.
